Trialsleap2semaglutideghrelinobesityclinicaltrials.gov

Danish trial tests LEAP2 against ghrelin signaling during semaglutide treatment

The randomized crossover study in people with obesity asks whether hunger signals stay active while a GLP-1 drug suppresses appetite.

By Priya Raman · Science Reporter

Oct 22 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT07171723, an early phase 1 crossover study sponsored by University Hospital Gentofte in Copenhagen, gave LEAP2 or placebo over two visits to people with obesity on semaglutide, starting September 2025 and now listed as completed.
02Endpoints include food intake, appetite sensations, glucose metabolism and hormonal responses, probing whether ghrelin-system blockade adds appetite suppression on top of a GLP-1.
03Results are not yet posted; this is a mechanistic early-phase study, not a test of LEAP2 as a weight-loss therapy.

From the source

Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment
NCT07171723 · EARLY_PHASE1 · COMPLETED · Sponsor: University Hospital, Gentofte, Copenhagen · Conditions: Obesity &Amp; Overweight.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07171723